Factors influencing urinary symptoms 10 years after permanent prostate seed implantation.

[1]  L. Potters,et al.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[2]  R. Stock,et al.  Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? , 2010, The Journal of urology.

[3]  V. Kataja,et al.  Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy--morbidity and outcome results. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  K. Bratengeier,et al.  Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: importance of baseline symptoms and of prostate-V150. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  P. Unger,et al.  Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. , 2008, International journal of radiation oncology, biology, physics.

[6]  Michael W Kattan,et al.  Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. , 2007, International journal of radiation oncology, biology, physics.

[7]  K. Wallner,et al.  The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy. , 2007, Brachytherapy.

[8]  D. Ash,et al.  A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  R. Stock,et al.  The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. , 2007, The Journal of urology.

[10]  R. Stock,et al.  Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation , 2006, BJU international.

[11]  M. Eble,et al.  Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. , 2006, Urology.

[12]  J. Logue,et al.  Prediction of urinary symptoms after 125iodine prostate brachytherapy. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  K. Wallner,et al.  Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy , 2006, BJU international.

[14]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[15]  P. Young,et al.  Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. , 2004, Mayo Clinic proceedings.

[16]  K. Wallner,et al.  Long-term urinary quality of life after permanent prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[17]  W. J. Morris,et al.  Predictive factors of urinary retention following prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[18]  J. Blasko,et al.  Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. , 2002, International journal of radiation oncology, biology, physics.

[19]  C. Catton,et al.  Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. , 2002, International journal of radiation oncology, biology, physics.

[20]  N Lee,et al.  Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[21]  W. Butler,et al.  Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[22]  R. Stock,et al.  Prostate brachytherapy: treatment strategies. , 1999, The Journal of urology.

[23]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[24]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[25]  G. Pond,et al.  Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.

[26]  Mark J Rivard,et al.  American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. , 2007, Brachytherapy.

[27]  K. Wallner,et al.  The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. , 2006, International journal of radiation oncology, biology, physics.

[28]  J. Blasko,et al.  Late urinary function after prostate brachytherapy. , 2002, Brachytherapy.

[29]  R. Stock,et al.  Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. , 1998, Radiation oncology investigations.